Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis.

Academic Article

Abstract

  • C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal immunoglobulin deposition caused by alternative complement pathway dysregulation. Unfortunately, no therapeutic intervention has consistently improved outcomes for patients with C3G. Eculizumab, a monoclonal antibody to C5, is currently the only approved complement-specific agent with some efficacy in the treatment of C3 glomerulonephritis (C3GN). Here, we describe a patient with acute crescentic C3GN with no identified complement mutation or family history of renal disease who required dialysis for 6 months. Five months after initiation of eculizumab, she became dialysis independent, showing improvement is possible after adequate time on eculizumab.
  • Published In

    Keywords

  • C3 glomerulopathy, alternative pathway, complement, eculizumab, end-stage renal disease
  • Digital Object Identifier (doi)

    Author List

  • Inman M; Prater G; Fatima H; Wallace E
  • Start Page

  • 445
  • End Page

  • 448
  • Volume

  • 8
  • Issue

  • 4